[HTML][HTML] Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: a case report
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial
growth factors have provided the basis for improved outcomes in select patients with …
growth factors have provided the basis for improved outcomes in select patients with …
Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
M Abdelrahim, A Esmail, G Umoru… - Current …, 2022 - mdanderson.elsevierpure.com
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial
growth factors have provided the basis for improved outcomes in select patients with …
growth factors have provided the basis for improved outcomes in select patients with …
Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
M Abdelrahim, A Esmail, G Umoru… - Current oncology …, 2022 - pubmed.ncbi.nlm.nih.gov
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial
growth factors have provided the basis for improved outcomes in select patients with …
growth factors have provided the basis for improved outcomes in select patients with …
Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.
M Abdelrahim, A Esmail, G Umoru… - Current Oncology …, 2022 - europepmc.org
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial
growth factors have provided the basis for improved outcomes in select patients with …
growth factors have provided the basis for improved outcomes in select patients with …
Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.
M Abdelrahim, A Esmail, G Umoru… - Current …, 2022 - search.ebscohost.com
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial
growth factors have provided the basis for improved outcomes in select patients with …
growth factors have provided the basis for improved outcomes in select patients with …
[HTML][HTML] Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
M Abdelrahim, A Esmail, G Umoru, K Westhart… - Current …, 2022 - ncbi.nlm.nih.gov
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial
growth factors have provided the basis for improved outcomes in select patients with …
growth factors have provided the basis for improved outcomes in select patients with …